Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cost-benefit and cost-effectiveness: methodologies for evaluating innovative pharmaceutical services.

W F McGhan, C R Rowland, J L Bootman

    American Journal of Hospital Pharmacy
    |February 1, 1978
    PubMed
    Summary

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer.

    British journal of cancer·2015
    Same author

    Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis.

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2013
    Same author

    Lipid-lowering pharmacoeconomic studies. Reactor panel and open forum.

    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2006
    Same author

    Employer and consumer perspectives.

    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2006
    Same author

    Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison.

    Archives of neurology·2001
    Same author

    Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder.

    The American journal of managed care·2001

    Evaluating innovative pharmaceutical services requires cost-benefit analysis. Further research is needed to maximize the societal benefit-to-cost ratio for these essential healthcare programs.

    Area of Science:

    • Health Economics
    • Pharmaceutical Services Evaluation
    • Pharmacoeconomics

    Background:

    • Innovative pharmaceutical services offer potential benefits but require rigorous evaluation.
    • Cost-benefit and cost-effectiveness analyses are crucial tools for assessing healthcare interventions.
    • Existing literature provides a foundation for evaluating pharmaceutical service value.

    Purpose of the Study:

    • To review cost-benefit and cost-effectiveness analysis techniques applicable to innovative pharmaceutical services.
    • To present a framework for conducting cost-benefit studies in pharmacy.
    • To appraise existing pharmacy studies utilizing these economic evaluation methods.

    Main Methods:

    • Review of cost-benefit and cost-effectiveness analysis methodologies.
    Keywords:
    AmericasCost Benefit AnalysisDeveloped CountriesDistributional ActivitiesEvaluationEvaluation MethodologyEvaluation ResearchLiterature ReviewNonclinical DistributionNorth AmericaNorthern AmericaOrganization And AdministrationPharmacy DistributionProgram ActivitiesProgramsQuantitative EvaluationUnited States

    Related Experiment Videos

  • Identification and discussion of process and outcome measures.
  • Presentation of suggested steps for conducting cost-benefit analyses.
  • Appraisal of sample pharmacy studies.

    • Main Results:

    • Several innovative pharmaceutical services, including ambulatory patient consultation, unit dose drug distribution, and drug therapy monitoring, were discussed.
    • Potential measures for both costs and benefits were identified, with literature references provided.
    • Encouraging reports on the cost-benefit of pharmaceutical services exist, but comprehensive data is limited.

    Conclusions:

    • Cost-benefit and cost-effectiveness analyses are valuable for evaluating pharmaceutical services.
    • Further evaluative research is essential to optimize the benefit-to-cost ratio of pharmaceutical services for society.
    • Developing programs that maximize the benefit-to-cost ratio requires continued investigation and robust data collection.